Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Foam Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Not applicable Interventional Results available

Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms

NCT03159260
View directory record Official record
Conditions
Leg Cramp, Nocturnal
Interventions
Theraworx, Placebo
Device · Other
Lead sponsor
Sport and Spine Rehab Clinical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

NCT00151515
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
minoxidil
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
15 Years to 49 Years · Male only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Vallejo, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 2 Interventional

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
Combination Product · Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional

Evaluation of Oral Simethicone With Low Volume Polyethylene Glycol Bowel Preparation During Colonoscopy

NCT03410524
View directory record Official record
Conditions
Colonoscopy
Interventions
Simethicone Solution, Water
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wayfinding Intervention in High-Fidelity Long-Term Memory

NCT04253587
View directory record Official record
Conditions
Long-Term Memory Decline, Mild Cognitive Impairment
Interventions
LabyrinthVR, Placebo Games, Coherence, Tablet
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
62 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis

NCT03770091
View directory record Official record
Conditions
Arthritis
Interventions
Theraworx, Placebo
Drug
Lead sponsor
John Fowler
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01231373
View directory record Official record
Conditions
Varicose Veins
Interventions
polidocanol injectable foam, 0.125%, polidocanol injectable foam, 0.5%, polidocanol injectable foam, 1.0%, Vehicle
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
Dothan, Alabama • San Diego, California • Lafayette, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

NCT01197833
View directory record Official record
Conditions
Great Saphenous Vein Incompetence, Visible Varicosities
Interventions
endovenous ablation+polidocanol injectable microfoam 0.125%, Endovenous ablation+polidocanol injectable microfoam 1.0%, Endovenous ablation+polidocanol injectable foam 2.0%
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Bradenton, Florida • Oak Brook, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 7, 2026, 11:46 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions
Vaginal Cream with Applicator
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 2 Interventional Results available

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

NCT02307916
View directory record Official record
Conditions
Tympanic Membrane Perforation
Interventions
FGF-2, Placebo
Drug · Other
Lead sponsor
D. Bradley Welling, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Lackland City, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
31
States / cities
Rogers, Arkansas • Fremont, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 7, 2026, 11:46 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

NCT02316249
View directory record Official record
Conditions
Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions
Estradiol, placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008410
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 2 Interventional

Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years

NCT01696799
View directory record Official record
Conditions
Interdigital Tinea Pedis
Interventions
Econazole Nitrate, placebo
Drug
Lead sponsor
AmDerma
Industry
Eligibility
12 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 7, 2026, 11:46 AM EDT
Withdrawn Phase 4 Interventional

The Effect of Theraworx Foam in Carpal Tunnel Syndrome

NCT04017390
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Theraworx Foam, Placebo Foam, Theraworx Foam and night splint, Placebo Foam and night time splint
Drug · Other
Lead sponsor
John Fowler
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

NCT01353976
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Foam 1%, Vehicle Foam
Drug · Other
Lead sponsor
AmDerma
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Not applicable Interventional Results available

Treatment of Staphylococcus Aureus Colonization in Hand Eczema

NCT01591785
View directory record Official record
Conditions
Hand Eczema, Foot Eczema
Interventions
Retapamulin 1% ointment, Placebo
Drug
Lead sponsor
Gary Goldenberg
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 7, 2026, 11:46 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 7, 2026, 11:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 7, 2026, 11:46 AM EDT